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Abstract
Background: Skeletal uptake of 99mTc labelled methylene diphosphonate (99mTc-MDP) is used for
producing images of pathological bone uptake due to its incorporation to the sites of active bone
turnover. This study was done to validate bone turnover markers using total skeletal uptake (TSU)
of 99mTc-MDP.
Methods: 22 postmenopausal women (52–80 years) volunteered to participate. Scintigraphy was
performed by injecting 520 MBq of 99mTc-MDP and taking whole body images after 3 minutes, and
5 hours. TSU was calculated from these two images by taking into account the urinary loss and soft
tissue uptake. Bone turnover markers used were bone specific alkaline phosphatase (S-Bone ALP),
three different assays for serum osteocalcin (OC), tartrate resistant acid phosphatase 5b (S-
TRACP5b), serum C-terminal cross-linked telopeptides of type I collagen (S-CTX-I) and three
assays for urinary osteocalcin (U-OC).
Results: The median TSU of 99mTc-MDP was 23% of the administered activity. All bone turnover
markers were significantly correlated with TSU with r-values from 0.52 (p = 0.013) to 0.90 (p <
0.001). The two resorption markers had numerically higher correlations (S-TRACP5b r = 0.90, S-
CTX-I r = 0.80) than the formation markers (S-Total OC r = 0.72, S-Bone ALP r = 0.66), but the
difference was not statistically significant. TSU did not correlate with age, weight, body mass index
or bone mineral density.
Conclusion: In conclusion, bone turnover markers are strongly correlated with total skeletal
uptake of 99mTc-MDP. There were no significant differences in correlations for bone formation and
resorption markers. This should be due to the coupling between formation and resorption.
Background
Bone metabolism can be assessed by biochemical means
using bone turnover markers (BTM) measured in serum or
urine [1]. BTMs can be used in the monitoring of antire-
sorptive therapy [2,3] and there is increasing evidence that
at least some BTMs can be predictive for bone loss [4] and
fracture [5,6]. They are, however, also subjected to rapid
changes due to reasons other than bone metabolism [7],
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such as diurnal variation, other tissue damages and food
intake [8]. Some of the BTMs reflect bone formation,
while others are associated to bone resorption. However,
both formation and resorption markers are usually
affected by changes in turnover due to the coupling
between these two processes [1].
Several attempts have been made to assess the skeletal
metabolic activity by using skeletal uptake of radiola-
belled, bone seeking, substances. Bisphosphonates, struc-
turally similar to the inorganic pyrophosphates in bone
matrix, have high affinity to bind to bone mineral [9].
Especially, they bind to the exposed sites that undergo
high bone turnover. Technetium-99m (99mTc) labelled
diphosphonates are commonly used in scintigraphic
uptake studies to detect lesions in conditions such as can-
cer metastasis, occult fractures and osteomyelitis due to
their high affinity to metabolically active sites in bone. In
these procedures the skeletal or extra-osseous accumula-
tion of 99mTc labelled methylene diphosphonate (99mTc-
MDP) is used to identify the lesions as "hot spots"
[10,11]. In earlier studies the measurement of 24-hour
whole body retention of 99mTc-MDP was used to assess
the skeletal metabolism [12,13], before introducing the
regional quantification of 99mTc-MDP activity by D'Add-
abbo et al [14] and Brenner et al [15]. These techniques
have been found to be useful techniques for estimating
skeletal turnover rate at the time of the measurement. The
regional quantification after 5-hours has the advantage
over 24-hour retention that it directly gives a measure of
skeletal uptake and a shorter time period is needed. To the
best of our knowledge, the correlation between bone
metabolism assessed by skeletal uptake of 99mTc-MDP and
by bone turnover markers has been evaluated only in a
few studies [13,16-18].
This study was designed to assess the correlation between
the skeletal uptake of 99mTc-MDP, and nine bone turnover
markers including markers of bone formation and bone
resorption and urinary osteocalcin. Our aim was to eluci-
date if markers reflect total skeletal turnover determined
by skeletal uptake of 99mTc-MDP. Furthermore, we aimed
to investigate if uptake of 99mTc-MDP is more related to
bone formation or resorption, assuming that if any of the
bone formation markers had a significantly greater corre-
lation with TSU, over the others; it could have been
regarded as a relatively specific measure of bone forma-
tion.
Methods
Participating women
22 postmenopausal women who had sought medical
advice or treatment for minor orthopaedic complains
(such as non-fracture trauma, back pain, vertebral frac-
tures, ankle fractures) at least 6 months before the recruit-
ment and who had never been treated with
bisphosphonates were selected from the registers of the
orthopaedic clinic at Malmö University Hospital. Patients
with primary hyperparathyroidism, hyperthyroidism,
osteomalacia, chronic malnutrition, any malignancy,
hepatic cirrhosis, joint prosthesis; or patients who had
been treated with systemic estrogens, therapeutic calcium,
vitamin D or corticosteroids within the last one year were
not included. When the study was started, they were free
from the condition that had originally brought them to
the clinic. Fractures within 2 years prior to the study were
also recorded.
Bone mineral density
Areal bone mineral density (BMD) of total body, lumbar
spine, femoral neck and bone mineral content (BMC) of
the total body were measured by dual-energy x-ray
absorptiometry (DXA) (Lunar DPX-L®  Madison, USA).
The precision of measurements assessed by duplicate
measurements on 15 elderly women after repositioning
were 0.5% for total body BMD, 1.3% for total body BMC,
1.2% for lumber spine BMD, and 3.9% for femoral neck
BMD.
Bone scintigraphy
Bone scintigraphy procedure was performed within 28
days after the DXA scanning according to a method
described by Brenner et al [15]. An injection of 520 (517
± 15) MBq of 99mTc-MDP (Medronate®, Amersham inter-
national) was given. The radio activity was measured in
the syringe both before and after injection to enable an
accurate determination of injected activity. Whole body
imaging was performed directly (3 minutes) after injec-
tion and 5 hours after injection. A double-headed gamma
camera system (Siemens Multispect 2) equipped with low
energy high-resolution collimators was used for the scan.
The scan speed was 40 cm/min for the image at 3 minutes
and 15 cm/min for the image after 5 hours. The images
were stored in a 1024 × 256 matrix for image processing.
Regions of interest (ROI) were drawn in the anterior and
posterior images to quantify the activity in whole body,
urinary bladder, and the adductor muscles of both thighs,
(Figure 1) as described by Brenner et al.[15]. The geomet-
ric mean of the anterior and posterior image was used in
the calculation of activity content and the 3-minute image
was used as a reference to calculate the percentage uptake
in the later image. For all data the numbers of counts in
the regions were corrected for decay of 99mTc. The soft tis-
sue activity was calculated from the adductor compart-
ment of both thighs as follows: activity of adductor
muscles at 5 hours divided by the activity of adductor
muscles at 3 minutes and multiplied by whole body activ-
ity at 3 minutes. All activity was considered to be excreted
from the body, only via urine. The excretion was calcu-BMC Medical Physics 2009, 9:3 http://www.biomedcentral.com/1756-6649/9/3
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lated from the difference in whole body activity between
two imaging times. Correction for radioactive decay and
scan speed was done. The total skeletal uptake (TSU) of
99mTc-MDP was calculated as (whole body radioactivity at
3 min – urinary excretion – soft tissue uptake at 5 hour)/
whole body radioactivity at 3 min × 100% [15].
Serum and urine samples for bone turnover markers
Non-fasting blood samples were collected before the scin-
tigraphy procedure (at 9.00 am). Serum was separated
within 2 hours after phlebotomy. Non-fasting urine sam-
ples were collected at 9.00 am. Serum and urine samples
were stored at -80°C for the analysis of bone turnover
markers.
Bone turnover markers
All the analyses were done at the same time. Bone-specific
alkaline phosphatase (S-Bone ALP) was determined by
using Metra BAP immunoassay (Quidel Corporation),
with an intra- and inter- assay CV of 3.6% and 4.4%,
respectively. Serum intact osteocalcin [S-OC(1–49)],
serum total osteocalcin (S-Total OC) and serum total
gamma-carboxylated osteocalcin (S-cOC) were deter-
mined by previously described, in-house protocols with
intra- and inter- assay CV of less than 5% and 8%, respec-
tively, for all the assays [19].
Serum C-terminal cross-linking telopeptides of type I col-
lagen (S-CTX-I) were determined by Elecsys β-Cross Laps®
immunoassay (Roche diagnostics) with intra- and inter-
assay CV of 5.9% and 5.8%, respectively. Serum tartrate-
resistant acid phosphatase 5b (S-TRACP5b) was assessed
by a solid phase, immunofixed, enzyme activity assay as
described earlier [20] with an intra- and inter- assay CV of
1.8% and 2.2%, respectively.
Three different assays of urinary osteocalcin, total osteo-
calcin (U-TotalOC), long osteocalcin (U-LongOC) and
Whole body scan images of one of the study participants at 3 minutes (A) and at 5 hours (B) Figure 1
Whole body scan images of one of the study participants at 3 minutes (A) and at 5 hours (B). Regions of interest 
(ROI) were drawn in the anterior and posterior images to quantify the activity in whole body, urinary bladder (X), and the 
adductor muscles of both thighs (Y), as described by Brenner et al.[15] Z = area marked for counting the background radiation.BMC Medical Physics 2009, 9:3 http://www.biomedcentral.com/1756-6649/9/3
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mid osteocalcin (U-MidOC) were analyzed as previously
published with intra- and inter- assay CVs of 14% and <
27% (U-TotalOC), 4.3% and < 14% (U-LongOC), and
1.7% and < 12% (U-MidOC), respectively [21].
Urinary creatinine was measured by the kinetic Jaffe reac-
tion with a Beckman synchron LX20-4, with CVs of 3% or
less. All the measurements of urinary osteocalcin were cor-
rected for urinary creatinine and expressed as ratios.
Statistical analysis
Statistica for Windows (version 7.1, Stat Soft Inc) software
was used for the statistical analysis. The results were
expressed as median and inter quartile range (IQR). The
correlations of bone turnover markers and the total skele-
tal uptake of 99mTc-MDP were assessed by using Spearman
rank correlations. Group comparisons were done using
Mann-Whitney U test. P-values less than 0.05 were con-
sidered statistically significant.
Ethics
All steps of the study were approved by the ethical review
committee, Lund University, Sweden in accordance with
the Declaration of Helsinki. Informed, consent was
obtained from each of the participants prior to the study.
Results
Basic characteristics
The median age of the women was 65 years (range 52–
80). The median total body BMD was 1.02 g/cm2 (IQR
0.97 – 1.08) (Table 1). Eight women had osteoporosis,
defined as T score ≤ -2.5 at spine (n = 7) or at femoral neck
(n = 1). Eight women had sustained a fracture within 2
years (range 0.5 – 2) before the study, including vertebral
compression fractures (n = 6), distal radius fracture (n = 1)
and ankle fracture (n = 1). Of them, five women had oste-
oporosis based on lumbar spine or femoral neck T-score.
Scintigraphy
The median value for total skeletal uptake of 99mTc-MDP
at 5 hours was 23% (IQR (18.8 – 27.9). There were no sta-
tistically significant associations between total skeletal
uptake and total body BMD, total body BMC, body
weight, BMI or age (Table 1).
Bone turnover markers
All the bone turnover markers were highly correlated with
total skeletal uptake of 99mTc-MDP with r-values from
0.52 for U-TotalOC (p = 0.013) to 0.90 for S-TRACP5b (p
< 0.001) (Table 1 and Figure 2). The two resorption mark-
ers had numerically higher correlations (S-TRACP5b r =
0.90, S-CTX-I r = 0.80) than the formation markers (S-
Table 1: Baseline characteristics, scintigraphy results and bone turnover markers of participants (n = 22).
Median (inter quartile range) Correlations with TSU of 99mTc-MDP
rp
Anthropometry
Age (years) 65 (59 – 73) 0.06 0.79
Height (cm) 162 (158 – 167) 0.03 0.90
Weight (kg) 65 (60 – 79) -0.08 0.071
BMI (kg/m2) 25.4 (22.8 – 29.1) -0.18 0.43
Bone mass
Total body BMC (g) 2075 (1933 – 2208) -0.23 0.30
Total body BMD (g/cm2) 1.02 (0.97 – 1.08) -0.36 0.10
Scintigraphy
Total skeletal uptake (%) 22.9 (18.8 – 27.9) - -
Bone Formation markers
S-Bone ALP (U/L) 23.0 (17.0 – 28.0) 0.66 < 0.001
S-Total OC (μg/L) 5.8 (5.0 – 8.5) 0.72 < 0.001
S-OC(1–49) (μg/L) 3.0 (2.2 – 5.0) 0.65 < 0.01
S-cOC (μg/L) 6.9 (5.4 – 9.1) 0.67 < 0.001
Bone resorption markers
S-TRACP5b (U/L) 3.1 (2.5 – 3.9) 0.90 < 0.001
S-CTX-I (ng/L) 228 (173 – 326) 0.80 < 0.001
Urine osteocalcin
U-Total OC/crea (μg/nmol) 28.3 (19.7 – 32.0) 0.52 0.013
U-Mid OC/crea (μg/nmol) 1.3 (0.9 – 2.0) 0.76 < 0.001
U-Long OC/crea (μg/nmol) 0.02 (0.01 – 0.04) 0.72 < 0.001
Results are shown as median values (interquartile range). Spearman rank correlations (r values) to total skeletal uptake (TSU) of 99mTc-MDP are 
also given.BMC Medical Physics 2009, 9:3 http://www.biomedcentral.com/1756-6649/9/3
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The association of total skeletal uptake (TSU) of 99mTc-MDP with (A) bone resorption marker, S-TRACP5b, r(spearman) = 0.90, p  < 0.001 and (B) bone formation marker, S-Total OC, r(spearman) = 0.72, p < 0.001 Figure 2
The association of total skeletal uptake (TSU) of 99mTc-MDP with (A) bone resorption marker, S-TRACP5b, 
r(spearman) = 0.90, p < 0.001 and (B) bone formation marker, S-Total OC, r(spearman) = 0.72, p < 0.001.
Table 2: Baseline characteristics, BMD, scintigraphy results and bone turnover markers in women with and without a recent fracture.
Women with a recent fracture (n = 8) Women without a recent fracture (n = 14) p
Anthropometry
Age (years) 62 (58 – 71) 66 (60 – 73) 0.54
Height (cm) 163 (159 – 168) 162 (157 – 167) 0.68
Weight (kg) 64 (61 – 69) 68 (57 – 84) 0.81
BMI (kg/m2) 24.2 (22.6 – 27.5) 26.5 (22.8 – 29.8) 0.41
Bone mass
Total body BMC (g) 1976 (1929 – 2051) 2127 (1960 – 2247) 0.207
Total body BMD (g/cm2) 0.97 (0.94 – 1.04) 1.04 (1.00 – 1.08) 0.041
Scintigraphy
Total skeletal uptake (%) 28.6 (21.3 – 31.8) 21.6 (17.0 – 24.8) 0.048
Bone formation Markers
S-Bone ALP (U/L) 27.0 (24.0 – 34.5) 21.0 (16.0 – 25.0) 0.034
S-Total OC (μg/L) 8.2 (5.5 – 13.3) 5.8 (4.4 – 7.3) 0.020
S-OC(1–49) (μg/L) 4.9 (3.0 – 10.0) 2.9 (2.1 – 4.4) 0.031
S-cOC (μg/L) 10.2 (6.6 – 16.5) 6.1 (5.3 – 7.8) 0.017
Bone resorption Markers
S-TRACP5b (U/L) 3.8 (2.9 – 5.2) 2.8 (2.4 – 3.7) 0.076
S-CTX-I (ng/L) 411 (186 – 639) 203 (173 – 253) 0.066
Urine Osteocalcin
U-Total OC/crea (μg/nmol) 30.5 (27.0 – 32.1) 25.5 (17.4 – 29.8) 0.13
U-Mid OC/crea (μg/nmol) 1.9 (1.3 – 2.4) 1.1 (0.9 – 1.7) 0.12
U-Long OC/crea (μg/nmol) 0.03 (0.01 – 0.08) 0.02 (0.01 – 0.03) 0.41
Results are shown as median values (inter quartile range). P values for Mann-Whitney U test are also given.BMC Medical Physics 2009, 9:3 http://www.biomedcentral.com/1756-6649/9/3
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Total OC r = 0.72, S-Bone ALP r = 0.66), but the difference
was not statistically significant.
Comparison of women with and without a recent fracture
We also compared women who had sustained a fracture
two years prior to the study (n = 8) to the other women (n
= 14). Women with a recent fracture had lower total body
BMD, higher TSU of 99mTc-MDP, and higher levels of
bone formation markers than women without a recent
fracture (Table 2). There were no significant differences in
anthropometry, BMC, bone resorption markers or U-OCs,
although the levels of resorption markers seemed to be
also slightly elevated in the fracture group.
Comparison of women with and without osteoporosis
There was no statistically significant difference in bone
turnover markers or in total skeletal uptake of 99mTc-MDP
between women with osteoporosis (n = 8) and other
women (n = 14) (data not shown).
Discussion
We have studied the association between nine bone turn-
over markers, representing different aspects of bone turn-
over, and total skeletal metabolism, as assessed by
scintigraphic measurement of total skeletal uptake of
99mTc-MDP. All bone turnover markers were highly corre-
lated to bone metabolism assessed by total skeletal uptake
of 99mTc-MDP.
S-TRACP5b and S-CTX-I, the markers of bone resorption,
were found to be numerically best correlated with TSU of
99mTc-MDP. The correlations for bone formation markers
were, however, also highly significant and it was not evi-
dent which of the bone turnover markers were associated
to total skeletal metabolism the most. Studies with 99mTc-
MDP suggest that MDP uptake reflects a combination of
skeletal blood flow and osteoblastic activity [22,23].
However, markers of bone formation not seemed to be
more correlated with such uptake than markers of bone
resorption. The lack of difference between formation and
resorption markers could be due to the coupling of these
two processes. Moreover, studies with radio-labelled
bisphosphonates have shown that bisphosphonates local-
ize to regions where new bone is being deposited and
newly formed crystals provide a surface area of exposed
mineral available to adsorb bisphosphonates, but are also
incorporated where osteoclasts are resorbing bone [24].
In addition, the precision and accuracy of the assays for
bone turnover markers differ. These differences in assay
performance may have influenced the correlations
between bone markers and TSU of 99mTc-MDP, making
the comparison of markers more difficult.
The highest r-value (0.90) was observed for S-TRACP5b.
TRACP5b is an enzyme produced by bone-resorbing oste-
oclasts and the activity of TRACP5b in serum reflects the
number of active osteoclasts [25,26]. The r-value for S-
CTX-I was almost as high (0.80) as for S-TRACP5b. CTX-I
results from cathepsin K-mediated degradation of type I
collagen by osteoclasts [27]. The number of bone-resorb-
ing osteoclasts (TRACP5b), as well as the amount of
degraded type I collagen (CTX-I) should be tightly corre-
lated to the rate of skeletal metabolism. The collection of
samples at non-fasting status may, however, have inter-
fered with the correlation for CTX-I, as it's levels are
known to be influenced by food intake [8].
The r-values for formation markers S-OC and S-bone ALP
were slightly lower (0.65 – 0.72). S-OC has a short half-
life in circulation [28] and it may be more susceptible to
preanalytical variability, such as in vitro degradation [29].
Moreover, circulating OC may contain molecules derived
from both formation and resorption processes [30]. Bone-
specific alkaline phosphatase is an enzyme originating
from osteoblasts and needed in osteoid formation and
mineralization. Although the methods currently available
detect preferentially the bone-specific isoform of the
enzyme, they still show a certain degree of cross-reactivity
between bone and liver isoforms [31]. The r-values for
two of the three urinary OC assays were of similar magni-
tude (0.72 and 0.76) than for serum OC (0.65, 0.67 and
0.72).
Previous studies on healthy individuals, individuals with
endocrine disorders (such as Cushing's syndrome, thyro-
toxicosis and primary hyperparathyroidism) or other skel-
etal diseases (such as heterotrophic pulmonary
ostoarthropathy) have shown TSU of 99mTc-MDP to be
correlated to conventional bone turnover markers such as
osteocalcin, urinary deoxypyridinoline [18], total alkaline
phosphatase, and urinary hydroxyproline [13,16-18] but
data on many currently available, more specific and sensi-
tive bone turnover markers has been lacking.
We did not detect correlation for TSU and age or for TSU
and BMD. Previous studies on healthy women, have
shown that the TSU of 99mTc-MDP is positively correlated
with age (n = 40, 84) [16,32] and negatively correlated
with BMD (n = 86) [33]. The absence of such correlation
in our study may be due to limited sample size.
When the women who had sustained fractures within two
years prior to the study were compared to the others,
women with recent fracture had higher level of bone for-
mation markers and higher level of TSU of 99mTc-MDP.
This is in line with our previous findings that bone forma-
tion markers remains elevated up to 1–2 years after frac-
ture [34,35]. Only one out of eight women had visible
focal uptake on the scintigram, on the site of prior frac-
ture. Most probably the increase of bone turnover in the
fractured individuals is due to the generalized post trau-BMC Medical Physics 2009, 9:3 http://www.biomedcentral.com/1756-6649/9/3
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matic skeletal process taking place after fracture [36] as
well local increase at the fracture site.
A main strength of this study is that we analyzed several
BTMs reflecting different aspects of bone metabolism. In
particular, the novel bone turnover markers such as S-
TRACP5b and urinary osteocalcins have not been evalu-
ated by using TSU of 99mTc-MDP in any of the earlier stud-
ies. There are also limitations. Small sample size hindered
us to compare which of the BTMs that correlated most
with TSU of 99mTc-MDP. This should be possible with
larger sample sizes, including also samples for relatively
high and low levels of formation and resorption, such as
children, and patients on anabolic treatments (high bone
formation rate), patients with osteolytic bone metastases
(high bone resorption rate) or patients on anti-resorptive
therapy (low bone formation and resorption rate).
Another limitation was with the scanning of scintigraphic
procedure used. When we take the whole body image at 3
min, with the speed of 40 cm/min, it took about 3 min-
utes for the camera to reach the thighs where soft tissue
uptake was calculated. It was assumed that 100% of radi-
oisotope is in soft tissue at this early image, but by this
time (approximately 6 minutes) some of radioisotope
could have already entered the skeleton or filtered by the
kidneys. When the study was initiated, information on the
effect of feeding on BTMs was not available. Samples were
collected without fasting and the non-fasting status may
have had minor influence on the results of a few markers,
in particular S-CTX-I [8]
Conclusion
In conclusion, biochemical markers of bone turnover are
strongly correlated with the skeletal metabolism as meas-
ured by TSU of 99mTc-MDP. Although 99mTc-MDP uptake
is largely driven by osteoblastic activity, there were no sig-
nificant differences in correlations between skeletal
uptake of 99mTc-MDP and bone formation markers or
bone resorption markers. This could be due to coupling
between formation and resorption.
Abbreviations
99mTc-MDP: Technitum 99m labelled methyline diphos-
phonate; TSU: Total skeletal uptake; BMD: Areal bone
mineral density; BMC: Bone mineral content; DXA: Dual
energy x-ray absorptiometry; IQR: Inter quartile range; S-
Bone ALP: Serum bone specific alkaline phosphatise; S-
Total OC: Serum total osteocalcin; S-OC(1–49): Serum
intact osteocalcin; S-cOC: Serum carboxylated osteocal-
cin; S-TRACP5b: Serum tartrate resistant acid phosphatase
5b; S-CTX-I: Serum C-terminal cross-linked telopeptides
of type I collagen; U-Total OC/crea: Urinary total osteocal-
cin to urinary creatinine ratio; U-Mid OC/crea: Urinary
mid osteocalcin to urinary creatinine ratio; U-Long OC/
crea: Urinary long osteocalcin to urinary creatinine ratio.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JL was responsible for the progress of the study, per-
formed the statistical analysis, interpreted the data and
wrote the manuscript. KN and OT performed the scintig-
raphy procedure, helped to draft the manuscript and
helped commenting on the manuscript. PW was involved
in planning of the study and helped to draft the manu-
script. KJO designed the study, and helped with interpre-
tation of results, and manuscript writing. KKI analysed the
bone turnover markers and was involved in interpretation
of results and writing of the manuscript. All authors have
read and approved the final manuscript.
Acknowledgements
This work received financial support from the Swedish Medical Research 
Council and the Helsingin Sanomain 100-vuotissäätiö Foundation, Finland.
References
1. Watts NB: Clinical utility of biochemical markers of bone
remodeling.  Clin Chem 1999, 45(8 Pt 2):1359-1368.
2. Bonnick SL, Shulman L: Monitoring osteoporosis therapy: bone
mineral density, bone turnover markers, or both?  Am J Med
2006, 119(4 Suppl 1):S25-31.
3. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-
Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, et al.:
Serum TRACP 5b is a useful marker for monitoring alendr-
onate treatment: comparison with other markers of bone
turnover.  J Bone Miner Res 2005, 20(10):1804-1812.
4. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P: Prediction of bone
loss using biochemical markers of bone turnover.  Osteoporos
Int 2007, 18(9):1297-1305.
5. Garnero P: Markers of bone turnover for the prediction of
fracture risk.  Osteoporos Int 2000, 11(Suppl 6):S55-65.
6. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A,
Pettersson K, Väänänen HK, Åkesson K, Obrant KJ: Biochemical
markers of bone metabolism and prediction of fracture in
elderly women.  J Bone Miner Res 2004, 19(3):386-393.
7. Hannon R, Eastell R: Preanalytical variability of biochemical
markers of bone turnover.  Osteoporos Int 2000, 11(Suppl
6):S30-44.
8. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R:
Effect of feeding on bone turnover markers and its impact on
biological variability of measurements.  Bone 2002,
30(6):886-890.
9. Papapoulos SE: Bisphosphonate actions: physical chemistry
revisited.  Bone 2006, 38(5):613-616.
10. Flores LG 2nd, Nagamachi S, Jinnouchi S, Ohnishi T, Futami S, Naka-
hara H, Tamura S: Relationship between extraosseous accumu-
lation in bone scintigraphy with 99Tcm-HMDP and
histopathology.  Nucl Med Commun 1998, 19(4):347-354.
11. Sahin M, Basoglu T, Bernay I, Yapici O, Canbaz F, Yalin T: Evaluation
of metastatic bone disease with pentavalent 99Tc(m)-dimer-
captosuccinic acid: a comparison with whole-body scanning
and 4/24 hour quantitation of vertebral lesions.  Nucl Med Com-
mun 2000, 21(3):251-258.
12. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR:
The use of whole-body retention of Tc-99m diphosphonate
in the diagnosis of metabolic bone disease.  J Nucl Med 1978,
19(3):270-275.
13. Thomsen K, Johansen J, Nilas L, Christiansen C: Whole body reten-
tion of 99mTc-diphosphonate. Relation to biochemical indi-
ces of bone turnover and to total body calcium.  Eur J Nucl Med
1987, 13(1):32-35.
14. D'Addabbo A, Rubini G, Mele M, Lauriero F: A new method for
assessing 99Tcm-MDP bone uptake from a bone scan image:Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Physics 2009, 9:3 http://www.biomedcentral.com/1756-6649/9/3
Page 8 of 8
(page number not for citation purposes)
quantitative measurement of radioactivity in global skeletal
regions of interest.  Nucl Med Commun 1992, 13(1):55-60.
15. Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M,
Henze E: Quantification of diphosphonate uptake based on
conventional bone scanning.  Eur J Nucl Med 1997,
24(10):1284-1290.
16. Carnevale V, Frusciante V, Scillitani A, Modoni S, Pileri M, Chiodini I,
Dicembrino F, Romagnoli E, Minisola S: Age-related changes in
the global skeletal uptake of technetium-99m methylene
diphosphonate in healthy women.  Eur J Nucl Med 1996,
23(11):1473-1477.
17. Minisola S, Pacitti MT, Romagnoli E, Rosso R, Carnevale V, Caravella
P, Scillitani A, Dicembrino F: Clinical validation of a new immu-
noradiometric assay for intact human osteocalcin.  Calcif Tis-
sue Int 1999, 64(5):365-369.
18. Scillitani A, Dicembrino F, Chiodini I, Minisola S, Fusilli S, Di Giorgio
A, Garrubba M, D'Aloiso L, Frusciante V, Torlontano M, et al.: Global
skeletal uptake of 99mTc-methylene diphosphonate (GSU)
in patients affected by endocrine diseases: comparison with
biochemical markers of bone turnover.  Osteoporos Int 2002,
13(10):829-834.
19. Käkönen SM, Hellman J, Karp M, Laaksonen P, Obrant KJ, Väänänen
HK, Lövgren T, Pettersson K: Development and evaluation of
three immunofluorometric assays that measure different
forms of osteocalcin in serum.  Clin Chem 2000, 46(3):332-337.
20. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen
HK: Tartrate-resistant acid phosphatase 5b: a novel serum
marker of bone resorption.  J Bone Miner Res 2000,
15(7):1337-1345.
21. Ivaska KK, Kakonen SM, Gerdhem P, Obrant KJ, Pettersson K,
Väänänen HK: Urinary osteocalcin as a marker of bone metab-
olism.  Clin Chem 2005, 51(3):618-628.
22. Moore AE, Blake GM, Fogelman I: Quantitative measurements of
bone remodeling using 99mTc-methylene diphosphonate
bone scans and blood sampling.  J Nucl Med 2008, 49(3):375-382.
23. Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I: Quantitative
studies of bone with the use of 18F-fluoride and 99mTc-
methylene diphosphonate.  Semin Nucl Med 2001, 31(1):28-49.
24. Masarachia P, Weinreb M, Balena R, Rodan GA: Comparison of the
distribution of 3H-alendronate and 3H-etidronate in rat and
mouse bones.  Bone 1996, 19(3):281-290.
25. Alatalo SL, Halleen JM, Hentunen TA, Monkkonen J, Väänänen HK:
Rapid screening method for osteoclast differentiation in
vitro that measures tartrate-resistant acid phosphatase 5b
activity secreted into the culture medium.  Clin Chem 2000,
46(11):1751-1754.
26. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Hal-
leen JM: Osteoclast-derived serum tartrate-resistant acid
phosphatase 5b in Albers-Schonberg disease (type II auto-
somal dominant osteopetrosis).  Clin Chem 2004, 50(5):883-890.
27. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel
O, Qvist P, Delmas PD, Foged NT, Delaisse JM: The type I collagen
fragments ICTP and CTX reveal distinct enzymatic path-
ways of bone collagen degradation.  J Bone Miner Res 2003,
18(5):859-867.
28. Price PA, Williamson MK, Lothringer JW: Origin of the vitamin K-
dependent bone protein found in plasma and its clearance by
kidney and bone.  J Biol Chem 1981, 256(24):12760-12766.
29. Garnero P, Grimaux M, Seguin P, Delmas PD: Characterization of
immunoreactive forms of human osteocalcin generated in
vivo and in vitro.  J Bone Miner Res 1994, 9(2):255-264.
30. Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K,
Väänänen HK: Release of intact and fragmented osteocalcin
molecules from bone matrix during bone resorption in vitro.
J Biol Chem 2004, 279(18):18361-18369.
31. Seibel MJ: Molecular markers of bone turnover: biochemical,
technical and analytical aspects.  Osteoporos Int 2000, 11(Suppl
6):S18-29.
32. Carnevale V, Dicembrino F, Frusciante V, Chiodini I, Minisola S, Scil-
litani A: Different patterns of global and regional skeletal
uptake of 99mTc-methylene diphosphonate with age: rele-
vance to the pathogenesis of bone loss.  J Nucl Med 2000,
41(9):1478-1483.
33. Kigami Y, Yamamoto I, Ohnishi H, Takada M, Matsushita R, Hamanaka
Y, Ota T, Morita R: Relationship between skeletal uptake of
99mTc-HMDP and bone mineral density in elderly women.
Ann Nucl Med 1998, 12(1):15-20.
34. Obrant KJ, Ivaska KK, Gerdhem P, Alatalo SL, Pettersson K, Väänänen
HK: Biochemical markers of bone turnover are influenced by
recently sustained fracture.  Bone 2005, 36(5):786-792.
35. Ivaska KK, Gerdhem P, Åkesson K, Garnero P, Obrant KJ: Effect of
fracture on bone turnover markers: a longitudinal study
comparing marker levels before and after injury in 113 eld-
erly women.  J Bone Miner Res 2007, 22(8):1155-1164.
36. Obrant KJ, Nilsson BE: Histomorphologic changes in the tibial
epiphysis after diaphyseal fracture.  Clin Orthop Relat Res
1984:270-275.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1756-6649/9/3/prepub